Melasma TA Gel (Niacinamide / Tranexamic Acid / Tretinoin) (30 mL)

Melasma TA Gel is a topical formulation designed to treat melasma and other hyperpigmentation disorders. It primarily contains Tranexamic Acid (TA), an antifibrinolytic agent that has shown effectiveness in reducing melanin production and improving the appearance of dark patches on the skin. It is often used as an alternative to traditional agents like hydroquinone, particularly in patients who cannot tolerate more irritating treatments.

Mechanisms of Action:
Tranexamic Acid works by inhibiting the plasminogen/plasmin pathway in skin cells. This action reduces melanocyte activity and the formation of melanin, leading to lightening of hyperpigmented areas. Unlike other depigmenting agents, TA works more gently and is less likely to cause irritation or rebound pigmentation, making it suitable for long-term use and sensitive skin types.

Contraindications & Precautions:
Melasma TA Gel should not be used in individuals with known hypersensitivity to tranexamic acid or any components of the gel. While topical TA has a good safety profile, it should be used with caution in patients with a history of clotting disorders when used systemically—though this risk is minimal with topical use.

Adverse Reactions / Side Effects:
Topical Tranexamic Acid is generally well-tolerated. Mild side effects may include skin irritation, dryness, redness, or itching at the site of application. Serious side effects are rare when used topically. If any signs of allergic reaction occur, such as swelling or severe rash, the product should be discontinued.

Pregnancy & Breastfeeding:
The safety of topical tranexamic acid during pregnancy and breastfeeding has not been fully established. While systemic tranexamic acid is sometimes used under medical supervision during pregnancy, the topical form should be used with caution. It is best to consult a healthcare provider before using Melasma TA Gel during pregnancy or lactation, and avoid applying near the chest area while breastfeeding.

Store this medication in its original container at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

1. Niaspan (niacin extended-release) tablet package insert. North Chicago, IL: Abbott Laboratories; 2015 Apr.
2. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-12.
3. Taylor AJ, Villines TC, Stanck EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009. Epub ahead of print, doi:10.1056/NEJMoa907569.
4. Lee JMS, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: A randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009;54:1787—94.
5. McKenney JM, et al. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7.
6. Lysteda (tranexamic acid) package insert. Parsippany, NJ: Ferring Pharmaceuticals Inc.; 2016 Mar.
7. Tranexamic acid in sodium chloride injection package insert. Lenoir, NC: Exela Pharma Sciences, LLC; 2019 Apr.
8. Vesanoid (tretinoin) capsules package insert. Nutley, NJ: Roche Laboratories Inc.; 2004 Oct.
9. Fisher GJ, Wang Z, Datta SC, et al. Pathophysiology of premature skin aging induced by ultraviolet light. N Engl J Med 1997;337:1419-28.
10. Grignani F, Fagioli M, Alcalay M, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994;83:10-25.
11. Colletti RB, Neufeld EJ, Roff NK, et al. Niacin treatment of hypercholesterolemia in children. Pediatrics 1993;92:78-82.
12. Expert Panel: National Cholesterol Education Program. Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 1992;89(suppl 2):525-84.
13. Niacinamide. In: Drugs in Pregnancy and Lactation. A Reference Guide to Fetal and Neonatal Risk. Briggs GG, Freeman RK, Yaffe SJ, (eds.) 7th ed., Philadelphia PA: Lippincott Williams and Wilkins; 2005:1140-1
14. Health Care Financing Administration. Interpretive Guidelines for Long-term Care Facilities. Title 42 CFR 483.25(l) F329: Unnecessary Drugs. Revised 2015.
15. Cyklokapron (tranexamic acid) package insert. New York, NY: Pfizer Injectables; 2017 Nov.
16. Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012;129:308-20.
17. Altreno (tretinoin lotion) package insert; Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2018 Aug.
18. Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002;25:345-72.
19. Tretinoin capsules package insert. Sellersville, PA: Teva Pharmaceuticals; 2009 Jun.
20. Retin-A Micro (tretinoin gel) package insert. Quebec, Canada: Valeant Pharmaceuticals North America, LLC; 2017 Oct.
21. Niaspan (niacin extended release) tablet package insert. North Chicago, IL: Abbott Laboratories; 2015 Apr.
22. Niacor (Niacin tablets) package insert. Minneapolis, MN: Upsher-Smith Laboratories, Inc.; 2000 Feb.
23. Tretinoin capsules package insert. Chestnut Ridge, NY: Par Pharmaceutical; 2017 Jan
24. Renova 0.02% (tretinoin cream) package insert; Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2013 Jun.